SCHEMBL5765072

SCHEMBL5765072

N#Cc1ccc(NC(=O)Cc2ccccc2)c(N)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
ALDH1A1 P00352 2/20 0.54
GAA P10253 2/20 0.54
KDM4E B2RXH2 1/20 0.54
HDAC3 O15379 2/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC2 Q92769 2/20 0.51
NCOR2 Q9Y618 2/20 0.51
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA5A P35218 3/20 0.50
CA7 P43166 3/20 0.50
CA5B Q9Y2D0 3/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
RORC P51449 1/20 0.48
HPGD P15428 2/20 0.48
MAPK8 P45983 3/20 0.47
RPS27 P42677 1/20 0.47
MAPK9 P45984 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5767127 0.80 PKM (0.61) LMNAALDH1A1GAAKMT2AMEN1
SCHEMBL8609928 0.78 HPGD (0.65) LMNAALDH1A1GAAKDM4EHDAC3
SCHEMBL20941573 0.77 FNTA (0.53) LMNAALDH1A1GAAKDM4EKMT2A
SCHEMBL5443977 0.77 RORC (0.72) LMNAALDH1A1GAAKDM4EHDAC3
SCHEMBL29767752 0.76 LMNA (1.00) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL6164465 0.75 LMNA (0.64) LMNAALDH1A1GAAKDM4EKMT2A
SCHEMBL7387168 0.75 KDM4E (0.51) ALDH1A1GAAKDM4EHDAC3HDAC1
SCHEMBL18132382 0.74 ALDH1A1 (0.62) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL7428403 0.74 MAPK8 (0.64) LMNAALDH1A1KDM4ERORCHPGD
SCHEMBL29065703 0.74 KMT2A (0.68) LMNAALDH1A1GAAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615636-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER INC. (US) 2006-01-18 EP disclosed
WO-2004089366-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER JAPAN, INC. (JP) 2004-10-21 WO disclosed
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists ANDO KAZUO (JP) 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists GRIN1, GRIN2B, GRIN2A LMNA 3923/4885ALDH1A1 1871/4885GAA 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.